Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211497
Status:
COMPLETED
Last Update Posted:
2005-09-21
First Post:
2005-09-13
Brief Title:
Safety and Efficacy of MBI 226 125 and 25 Topical Acne Solutions in the Treatment of Acne
Sponsor:
BioWest Therapeutics Inc
Organization:
BioWest Therapeutics Inc
Study Overview
Official Title:
A Phase II Randomized Vehicle-Controlled Double-Blind Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 125 and 25 Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II randomized vehicle-controlled double-blind multi center study to evaluate the efficacy and safety of topically applied MBI 226 125 and 25 Acne Solutions as anti-acne preparations in human subjects with facial acne vulgaris
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None